-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-09-29
The referenced preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by stabilizing a phosphatase-accessible activation-loop conformation. This structural mechanism offers a framework for designing inhibitors that combine active-site inhibition with enhanced control of kinase deactivation, although its relevance to cellular and disease models remains to be established.
-
PF-562271 HCl for FAK/Pyk2 Research
2026-09-28
PF-562271 HCl enables reversible, selective perturbation of FAK/Pyk2 signaling in tumor-cell, migration, and tumor-microenvironment assays. This workflow connects pathway-level pharmacology with radiotherapy–checkpoint studies while clearly separating established evidence from hypothesis-generating combination experiments.
-
Puromycin dihydrochloride: Practical Selection Guide
2026-09-28
Puromycin dihydrochloride is an aminonucleoside antibiotic used to select cells carrying the pac gene and to inhibit translation in controlled experiments. Use a cell-specific kill curve rather than a universal puromycin selection concentration; it is not a reversible inhibitor, and cytotoxicity alone does not establish an autophagy or ribosome-related effect.
-
BMAL1 Phase Separation Organizes Circadian Transcription
2026-09-27
Gao and colleagues identify BMAL1 as a phase-separating clock protein whose dynamic condensates recruit transcriptional machinery and support rhythmic gene expression. Their cell and mouse rescue experiments connect an N-terminal disordered region to circadian function, while phosphorylation emerges as a regulator of condensate formation.
-
L-NMMA acetate for NOS Pathway Experiments
2026-09-26
Use L-NMMA acetate to test whether nitric oxide synthase activity is necessary for a cellular response—not simply associated with it. A practical workflow, anchored to research in rat dental follicle cells, combines dose-finding with viability, nitric oxide, cGMP, and osteogenic readouts.
-
MRT68921: A ULK1 Kinase Inhibitor for Autophagy Studies
2026-09-25
Use MRT68921 to test whether ULK1/2-dependent autophagy initiation contributes to a cellular phenotype—not simply whether LC3 levels change. This guide pairs target-proximal ATG13 phosphorylation with LC3-flux controls and practical safeguards for interpreting energy-stress experiments.
-
MOB1A/B Loss Disrupts Intestinal Epithelial Homeostasis
2026-09-25
Bae and colleagues show that intestinal epithelial depletion of MOB1A/B is associated with reduced Wnt activity, increased YAP activity, and activation of BMP/TGF-β signaling. Pharmacological inhibition partially improved epithelial degeneration and secretory-lineage differentiation, but did not restore the intestinal stem-cell pool, highlighting both the value and limits of pathway-level rescue.
-
JXY Drives M1 Polarization in Colitis-Associated Cancer
2026-09-24
Liu et al. report that Jiedu Xiaozheng Yin (JXY) reduced tumor burden and tissue injury in a mouse model of colitis-associated colorectal cancer, alongside macrophage changes consistent with TLR4-linked M1 polarization. The combined animal and cell-based evidence supports an immune-modulation hypothesis, while leaving important questions about the active components, signaling sequence, and human relevance unresolved.
-
Prenatal Nanoplastics Disrupt Offspring Vascular Lipid Balan
2026-09-24
A mouse study links prenatal and lactational exposure to 100-nm polystyrene nanoplastics with lipid accumulation in the aortic media of male offspring, and identifies MAPK/ERK and UHRF1 as candidate mediators. Pharmacological inhibition and UHRF1 knockdown support this pathway in cultured vascular smooth muscle cells, while leaving important questions about exposure relevance and long-term cardiovascular outcomes unresolved.
-
Exo1 for Membrane Trafficking Assays
2026-09-23
Exo1 offers an acute way to perturb Golgi–ER membrane traffic and study exocytosis without reproducing Brefeldin A’s full profile. This workflow explains how to use it as a controlled cell-assay perturbation—and how to interpret results cautiously when investigating tumor extracellular vesicles.
-
ETS1–SENP2 Axis in Bronchopulmonary Dysplasia
2026-09-23
The reference study identifies ETS1 as a transcriptional regulator that protects developing lungs from hyperoxia-associated mitochondrial injury by activating the SENP2/HSPA8/FUNDC1 pathway. Its genetic perturbation strategy links FUNDC1 deSUMOylation and degradation to suppression of excessive mitophagy, providing a mechanistic framework for studying mitochondrial quality control in bronchopulmonary dysplasia.
-
UHRF1, Super-Enhancers, and Osteogenesis in Osteoporosis
2026-09-22
The reference study identifies a mechanistic connection between UHRF1-dependent DNA 5-methylcytosine, super-enhancer redistribution, TGM2 signaling, and autophagic flux in senile osteoporosis. Its integrated multi-omics and in vivo strategy suggests that the UHRF1–TGM2 axis can influence mesenchymal stem cell osteogenesis and may provide a framework for testing epigenetic interventions in bone loss.
-
Bobcat339 for TET-Mediated DNA Methylation
2026-09-22
Bobcat339 provides a reversible chemical route to probe TET1/TET2-dependent DNA methylation regulation alongside transcriptomic, chromatin, and osteogenic assays. Its value is greatest when biochemical inhibition, cellular dose–response, and locus-level readouts are interpreted together rather than treated as interchangeable evidence.
-
U 46619: Platelet and Vascular Assay Workflows
2026-09-21
U 46619 converts TP-receptor activation into a practical, time-resolved platform for platelet aggregation, serotonin release, and vascular reactivity studies. This workflow-focused guide shows how to separate early signaling from downstream functional responses while improving solvent control, dosing logic, and assay reproducibility.
-
Phosphatase Inhibitor Cocktail 2 for Autophagy
2026-09-21
Phosphatase Inhibitor Cocktail 2 protects phosphorylation-dependent readouts in autophagy and hepatic lipid signaling studies. Learn how to pair phosphatase control with mechanistic insights from the SREBP-1c–CSE–ULK1 pathway without confusing phosphorylation with sulfhydration.